Replimune Group Inc.(REPL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REPL Replimune Group Inc.

交易中 04-02 13:22:22 EDT

8.18

+0.57

+7.42%

最高8.22	最低7.68	成交量123.81万
今开7.70	昨收7.61	日振幅7.16%
总市值6.75亿	流通市值4.08亿	总股本8,257万
成交额992.23万	换手率2.48%	流通股本4,997万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"REPL","market":"US","secType":"STK","nameCN":"Replimune Group Inc.","latestPrice":8.175,"timestamp":1775150529909,"preClose":7.61,"halted":0,"volume":1238064,"delay":0,"changeRate":0.07424441524310123,"floatShares":49968589,"shares":82572600,"eps":-3.435956,"marketStatus":"交易中","change":0.565,"latestTime":"04-02 13:22:22 EDT","open":7.7,"high":8.22,"low":7.675,"amount":9922306.693872001,"amplitude":0.071616,"askPrice":8.19,"askSize":9,"bidPrice":8.16,"bidSize":408,"shortable":3,"etf":0,"ttmEps":-3.435956,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1775160000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1532059200000,"exchange":"NASDAQ","adjPreClose":7.61,"preHourTrading":{"tag":"盘前","latestPrice":7.71,"preClose":7.61,"latestTime":"09:29 EDT","volume":3274,"amount":24960.8623922,"timestamp":1775136599999,"change":0.1,"changeRate":0.013141,"amplitude":0.047306},"postHourTrading":{"tag":"盘后","latestPrice":7.8872,"preClose":7.61,"latestTime":"19:55 EDT","volume":14484,"amount":110543.581,"timestamp":1775087715639,"change":0.2772,"changeRate":0.036426,"amplitude":0.038108},"volumeRatio":1.507688,"optionData":{"bulkOrders":[{"symbol":"REPL","call":true,"expireDate":1776398400000,"strike":"13.0","timestamp":1775145088973,"price":1.3,"volume":6600,"amount":858000,"type":"+"}]},"impliedVol":2.7524,"impliedVolPercentile":0.9283},"requestUrl":"/m/hq/s/REPL","defaultTab":"news","newsList":[{"id":"2605181514","title":"Replimune Group, Inc.盘中异动 急速上涨5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605181514","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605181514?lang=zh_cn&edition=full","pubTime":"2026-01-22 23:17","pubTimestamp":1769095068,"startTime":"0","endTime":"0","summary":"北京时间2026年01月22日23时17分，Replimune Group, Inc.股票出现波动，股价急速拉升5.37%。Replimune Group, Inc.股票所在的生物技术行业中，整体涨幅为1.05%。其相关个股中，60 Degrees Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Cabaletta Bio, Inc.涨幅较大，60 Degrees Pharmaceuticals, Inc.、Oragenics Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为11352.19%、367.35%、284.48%，振幅较大的相关个股有60 Degrees Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为131.00%、69.40%、36.70%。Replimune Group, Inc.公司简介：Replimune Group Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122231748a6a12932&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122231748a6a12932&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192482852","title":"Replimune Group第二季度净亏损8310万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192482852","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192482852?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:58","pubTimestamp":1763571497,"startTime":"0","endTime":"0","summary":"11月6日 - Replimune Group第二季度运营费用为8429.1万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582484773","title":"Replimune Group, Inc.盘中异动 大幅拉升5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582484773","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582484773?lang=zh_cn&edition=full","pubTime":"2025-11-12 00:10","pubTimestamp":1762877430,"startTime":"0","endTime":"0","summary":"北京时间2025年11月12日00时10分，Replimune Group, Inc.股票出现异动，股价大幅拉升5.05%。Replimune Group, Inc.股票所在的生物技术行业中，整体涨幅为1.11%。其相关个股中，Engene Holdings Inc C/Wts 31/10/2028  Cl A、Engene Holdings Inc.、Xbiotech Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aspire Biopharma Holdings, Inc.、Salarius Pharmaceuticals, Inc.较为活跃，换手率分别为2691.76%、356.53%、310.40%，振幅较大的相关个股有Engene Holdings Inc C/Wts 31/10/2028  Cl A、Quoin Pharmaceuticals Ltd、Engene Holdings Inc.，振幅分别为75.38%、58.48%、54.91%。Replimune Group, Inc.公司简介：Replimune Group Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511120010319762d726&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511120010319762d726&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2577652535","title":"Replimune Group, Inc.盘中异动 早盘股价大涨5.06%报8.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577652535","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577652535?lang=zh_cn&edition=full","pubTime":"2025-10-23 21:42","pubTimestamp":1761226940,"startTime":"0","endTime":"0","summary":"北京时间2025年10月23日21时42分，Replimune Group, Inc.股票出现波动，股价急速上涨5.06%。截至发稿，该股报8.72美元/股，成交量45.7567万股，换手率0.59%，振幅4.23%。Replimune Group, Inc.股票所在的生物技术行业中，整体跌幅为0.10%。Replimune Group, Inc.公司简介：Replimune Group Inc 是一家临床阶段的生物技术公司。消息层面，截至21时42分，《Leerink Partners上调Replimune至买入评级，上调目标价至13美元》资讯为影响Replimune Group, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102321422094d9d68b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102321422094d9d68b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REPL","VTYX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183771911","title":"异动解读 | Replimune Group股价盘中大涨5.20%，多家券商上调评级及目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1183771911","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183771911?lang=zh_cn&edition=full","pubTime":"2025-10-21 21:32","pubTimestamp":1761053557,"startTime":"0","endTime":"0","summary":"生物医药公司Replimune Group Inc今日股价表现强劲，盘中大涨5.20%，引起市场广泛关注。消息面上，多家知名券商对Replimune Group给予了积极评级。这些利好评级显示华尔街分析师对Replimune Group未来发展前景持乐观态度。分析人士认为，券商评级的上调可能反映出Replimune Group在肿瘤免疫疗法研发方面取得了积极进展。作为一家专注于开发新一代肿瘤溶解免疫疗法的生物技术公司，Replimune Group的研发成果对公司未来发展至关重要。投资者对公司潜力的认可推动了股价的强劲上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"26c657bd6894c690b20c7751c141e52e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143237081","title":"Replimune Group Inc：Piper Sandler将评级从中性上调至增持；目标价从8美元上调至13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143237081","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143237081?lang=zh_cn&edition=full","pubTime":"2025-10-21 12:17","pubTimestamp":1761020229,"startTime":"0","endTime":"0","summary":"Replimune Group Inc：Piper Sandler将评级从中性上调至增持；目标价从8美元上调至13美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113640990","title":"异动解读 | Replimune集团股价盘中飙升100%，皮肤癌新药申请获FDA接受","url":"https://stock-news.laohu8.com/highlight/detail?id=1113640990","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113640990?lang=zh_cn&edition=full","pubTime":"2025-10-20 22:02","pubTimestamp":1760968944,"startTime":"0","endTime":"0","summary":"生物技术公司Replimune Group Inc周一股价表现亮眼，盘中大涨100.76%，引发市场广泛关注。这一显著涨幅主要源于该公司在新药开发方面取得重大进展。据悉，美国食品药品监督管理局已接受Replimune重新提交的实验性疗法RP1的审批申请。FDA此次接受申请为该药物的潜在批准铺平了道路，预计将于明年4月10日前对该药物做出决定。这一消息对Replimune来说意义重大。值得注意的是，在此利好消息公布之前，Replimune的股价今年以来已累计下跌62.8%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"26c657bd6894c690b20c7751c141e52e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122482588","title":"生物技术公司Replimune盘初飙升，其新药审批申请获得FDA的接受","url":"https://stock-news.laohu8.com/highlight/detail?id=1122482588","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122482588?lang=zh_cn&edition=full","pubTime":"2025-10-20 21:57","pubTimestamp":1760968668,"startTime":"0","endTime":"0","summary":"接受了其皮肤癌药物重新提交的审批申请。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"26c657bd6894c690b20c7751c141e52e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162796164","title":"Replimune 股价在美国 FDA 接受皮肤癌药物潜在批准重新提交后翻倍，最新涨幅为106.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162796164","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162796164?lang=zh_cn&edition=full","pubTime":"2025-10-20 21:39","pubTimestamp":1760967551,"startTime":"0","endTime":"0","summary":"Replimune 股价在美国 FDA 接受皮肤癌药物潜在批准的重新提交后，涨幅超过一倍，最新上涨106.2%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"26c657bd6894c690b20c7751c141e52e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131372511","title":"Replimune Group股票在盘前上涨75.8%，因美国FDA接受皮肤癌药物的重新提交申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1131372511","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131372511?lang=zh_cn&edition=full","pubTime":"2025-10-20 19:30","pubTimestamp":1760959810,"startTime":"0","endTime":"0","summary":"Replimune Group股票在盘前上涨75.8%，因美国FDA接受了该公司皮肤癌药物的重新提交申请，从而为潜在批准铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"26c657bd6894c690b20c7751c141e52e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163806006","title":"新闻稿：Replimune在与FDA Type A会议后发布最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1163806006","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163806006?lang=zh_cn&edition=full","pubTime":"2025-09-18 21:17","pubTimestamp":1758201435,"startTime":"0","endTime":"0","summary":"公司正在评估会议期间FDA提供的反馈意见，以确定下一步行动。目前，尚未确定在加速审批途径下的前进路径。Replimune首席执行官Sushil Patel博士表示：\"来自黑色素瘤医学界包括患者和医生的反馈，清楚地强调了晚期黑色素瘤存在的未满足医疗需求，以及在IGNYTE试验中观察到的RP1令人信服的获益风险特征。Replimune的专有RPx平台基于强效的HSV-1骨架，旨在最大化免疫原性细胞死亡和诱导全身抗肿瘤免疫反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0390134368.USD","LU0757428866.USD","CRL","REPL","BK4530","BK4588","LU1815336091.USD","BK4121","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516668787","title":"Replimune Group, Inc.盘中异动 急速跳水5.13%报12.03美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516668787","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516668787?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:10","pubTimestamp":1741032617,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时10分，Replimune Group, Inc.股票出现异动，股价急速下跌5.13%。截至发稿，该股报12.03美元/股，成交量30.7721万股，换手率0.40%，振幅8.83%。Replimune Group, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Celularity Inc C/Wts 16/07/2026 涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4590.81%、212.56%、182.81%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Replimune Group, Inc.公司简介：Replimune Group Inc是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041017abe69136&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041017abe69136&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516706583","title":"Replimune Group, Inc.盘中异动 大幅下跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516706583","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516706583?lang=zh_cn&edition=full","pubTime":"2025-03-01 01:46","pubTimestamp":1740764777,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日01时46分，Replimune Group, Inc.股票出现波动，股价大幅下挫5.03%。Replimune Group, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Camp4 Therapeutics Corporation涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为3119.37%、511.46%、374.69%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 ，振幅分别为57.80%、49.50%、48.19%。Replimune Group, Inc.公司简介：Replimune Group Inc是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301014617a25830af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301014617a25830af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514865334","title":"Replimune Group, Inc.盘中异动 下午盘股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514865334","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514865334?lang=zh_cn&edition=full","pubTime":"2025-02-28 03:41","pubTimestamp":1740685271,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日03时41分，Replimune Group, Inc.股票出现波动，股价急速下跌5.02%。Replimune Group, Inc.股票所在的生物技术行业中，整体跌幅为0.23%。其相关个股中，Pepgen Inc.、Alpha Tau Medical Ltd C/Wts 、Ibio, Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Vincerx Pharma, Inc.较为活跃，换手率分别为1907.10%、331.35%、184.86%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pepgen Inc.、Pds Biotechnology Corporation，振幅分别为86.14%、67.32%、55.84%。Replimune Group, Inc.公司简介：Replimune Group Inc是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228034111abdfb2d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228034111abdfb2d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514857702","title":"小摩：维持Replimune Group(REPL.US)评级，由增持调整至增持评级, 目标价由16.00美元调整至18.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514857702","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514857702?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:23","pubTimestamp":1740587009,"startTime":"0","endTime":"0","summary":"小摩：维持Replimune Group(REPL.US)评级，由增持调整至增持评级, 目标价由16.00美元调整至18.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27002348413726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513196202","title":"Replimune Group, Inc.盘中异动 急速下挫5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513196202","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513196202?lang=zh_cn&edition=full","pubTime":"2025-02-22 02:52","pubTimestamp":1740163926,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日02时52分，Replimune Group, Inc.股票出现波动，股价大幅下跌5.17%。Replimune Group, Inc.股票所在的生物技术行业中，整体涨幅为0.27%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Revolution Medicines Inc C/Wts 17/12/2026 、Invivyd, Inc.涨幅较大，Aditxt, Inc.、Nkgen Biotech, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为292.25%、247.52%、136.45%，振幅较大的相关个股有Osr Holdings, Inc.、Invivyd, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为76.52%、70.25%、61.26%。Replimune Group, Inc.公司简介：Replimune Group Inc是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222025206962bb439&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222025206962bb439&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511540882","title":"HC Wainwright & Co.：维持Replimune Group(REPL.US)评级，由买入调整至买入评级, 目标价由21.00美元调整至22.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511540882","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511540882?lang=zh_cn&edition=full","pubTime":"2025-02-13 21:24","pubTimestamp":1739453047,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Replimune Group(REPL.US)评级，由买入调整至买入评级, 目标价由21.00美元调整至22.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/13212448148730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510372470","title":"Replimune Group(REPL.US)：2025年Q3财报实现营收0美元，前值为0美元；每股收益为-0.79美元，前值为-0.77美元，预期值为-0.75美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510372470","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510372470?lang=zh_cn&edition=full","pubTime":"2025-02-12 21:54","pubTimestamp":1739368470,"startTime":"0","endTime":"0","summary":"Replimune Group(REPL.US)：2025年Q3财报实现营收0美元，前值为0美元；每股收益为-0.79美元，前值为-0.77美元，预期值为-0.75美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/12215448121698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135702823","title":"Replimune集团第三季度每股收益$(0.79)不及预期$(0.71)","url":"https://stock-news.laohu8.com/highlight/detail?id=1135702823","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135702823?lang=zh_cn&edition=full","pubTime":"2025-02-12 21:06","pubTimestamp":1739365588,"startTime":"0","endTime":"0","summary":"Replimune集团第三季度每股收益达$(0.79)，低于预期的$(0.71)以上内容来自Benzinga Earnings专栏，原文如下：Replimune Group Q3 EPS $(0.79) Misses $(0.71) Estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Replimune集团第三季度每股收益$(0.79)不及预期$(0.71)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510910188","title":"Replimune Group, Inc.盘中异动 急速下挫5.09%报13.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510910188","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510910188?lang=zh_cn&edition=full","pubTime":"2025-02-11 03:45","pubTimestamp":1739216725,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日03时45分，Replimune Group, Inc.股票出现异动，股价大幅下挫5.09%。截至发稿，该股报13.23美元/股，成交量46.1384万股，换手率0.60%，振幅5.02%。Replimune Group, Inc.股票所在的生物技术行业中，整体跌幅为0.91%。其相关个股中，Dominari Holdings Inc.、知临集团、Biodexa Pharmaceuticals Plc涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为3153.90%、1679.05%、1421.36%，振幅较大的相关个股有Immatics N V C/Wts 01/07/2025 、Biodexa Pharmaceuticals Plc、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为99.86%、92.63%、87.80%。Replimune Group, Inc.公司简介：Replimune Group Inc是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211034525961e3a11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211034525961e3a11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.replimune.com","stockEarnings":[{"period":"1week","weight":0.0066},{"period":"1month","weight":0.0628},{"period":"3month","weight":-0.2171},{"period":"6month","weight":0.6089},{"period":"1year","weight":-0.094},{"period":"ytd","weight":-0.2171}],"compareEarnings":[{"period":"1week","weight":-0.0024},{"period":"1month","weight":-0.0454},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0209},{"period":"1year","weight":0.168},{"period":"ytd","weight":-0.0391}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Replimune Group, Inc.于2015年在特拉华州注册成立。该公司是一家临床阶段的生物技术公司，致力于应用他们在溶瘤免疫治疗领域的领先专业技术，改变癌症患者的生活。使用该公司专有的Immulytic平台来设计和开发旨在最大限度激活免疫系统对抗癌症的候选产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":-0.013766},{"month":2,"riseRate":0.375,"avgChangeRate":-0.050762},{"month":3,"riseRate":0.25,"avgChangeRate":-0.088086},{"month":4,"riseRate":0.5,"avgChangeRate":0.103202},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.048711},{"month":6,"riseRate":0.857143,"avgChangeRate":0.223071},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.088436},{"month":8,"riseRate":0.375,"avgChangeRate":0.023484},{"month":9,"riseRate":0.25,"avgChangeRate":-0.055352},{"month":10,"riseRate":0.625,"avgChangeRate":0.268092},{"month":11,"riseRate":0.625,"avgChangeRate":0.036282},{"month":12,"riseRate":0.25,"avgChangeRate":-0.087028}],"exchange":"NASDAQ","name":"Replimune Group Inc.","nameEN":"Replimune Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Replimune Group Inc.(REPL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Replimune Group Inc.(REPL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Replimune Group Inc.,REPL,Replimune Group Inc.股票,Replimune Group Inc.股票老虎,Replimune Group Inc.股票老虎国际,Replimune Group Inc.行情,Replimune Group Inc.股票行情,Replimune Group Inc.股价,Replimune Group Inc.股市,Replimune Group Inc.股票价格,Replimune Group Inc.股票交易,Replimune Group Inc.股票购买,Replimune Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Replimune Group Inc.(REPL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Replimune Group Inc.(REPL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}